{
    "name": "baricitinib",
    "comment": "Rx",
    "other_names": [
        "Olumiant"
    ],
    "classes": [
        "DMARDs",
        "JAK Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/olumiant-baricitinib-1000107",
    "pregnancy": {
        "common": [
            "Report pregnancies to Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979)",
            "Based on findings from animal reproduction studies, therapy may cause fetal harm during pregnancy; available data from clinical trials and postmarketing reports of exposure in pregnancy are insufficient to inform a drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes",
            "There are no human data on chronic baricitinib exposure throughout pregnancy; there are risks to mother and the fetus associated with rheumatoid arthritis in pregnancy; consider risks and benefits with chronic use during pregnancy",
            "Published data suggest that increased disease activity is associated with risk of developing adverse pregnancy outcomes in women with rheumatoid arthritis; adverse pregnancy outcomes include preterm delivery (before 37 weeks of gestation), low birth weight (less than 2500 g) infants, and small for gestational age at birth",
            "Based on animal studies, therapy may cause fetal harm when administered during pregnancy; consider pregnancy planning and prevention for females of reproductive potential"
        ],
        "specific": [
            {
                "type": "Animal studies",
                "description": [
                    "In animal embryo-fetal development studies, oral baricitinib administration to pregnant rats and rabbits at exposures equal to and greater than ~20 and 84 times the maximum recommended human dose (MRHD), respectively, resulted in reduced fetal body weights, increased embryo lethality (rabbits only), and dose-related increases in skeletal malformations"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Unknown if distributed in human breast milk",
            "Baricitinib is present in the milk of lactating rats",
            "Owing to species-specific differences in lactation physiology, the clinical relevance of these data are not clear",
            "Because of the potential for serious adverse reactions in nursing infants, advise women with rheumatoid arthritis not to breastfeed while taking baricitinib"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Serious infections",
                    "description": [
                        "May increase risk for developing serious infections which may lead to hospitalization or death",
                        "Most patients with rheumatoid arthritis who developed these infections were taking concomitant immunosuppressants (eg, methotrexate, corticosteroids)",
                        "If a serious infection develops, interrupt dosing until infection is controlled",
                        "Reported infections include:",
                        "Active TB, which may present with pulmonary or extrapulmonary disease; do not administer to patients with active TB ",
                        "Except those with COVID-19, test for latent TB before initiating and during therapy; consider treating for latent infection before initiating",
                        "Invasive fungal infections, including candidiasis and pneumocystosis; patients with invasive fungal infections may present with disseminated, rather than localized, disease",
                        "Bacterial, viral, and other infections due to opportunistic pathogens",
                        "Consider risks and benefits before initiating therapy in patients with chronic or recurrent infection",
                        "Closely monitor for developing signs and symptoms of infection during and after treatment, including the possible development of TB in patients who tested negative for latent TB before initiating baricitinib "
                    ]
                },
                {
                    "type": "Mortality and cardiovascular risk",
                    "description": [
                        "Active TB, which may present with pulmonary or extrapulmonary disease; do not administer to patients with active TB ",
                        "Except those with COVID-19, test for latent TB before initiating and during therapy; consider treating for latent infection before initiating",
                        "Invasive fungal infections, including candidiasis and pneumocystosis; patients with invasive fungal infections may present with disseminated, rather than localized, disease",
                        "Bacterial, viral, and other infections due to opportunistic pathogens"
                    ]
                },
                {
                    "type": "Malignancies",
                    "description": [
                        "Higher rate of all-cause mortality observed, including sudden cardiovascular (CV) death, with another JAK inhibitor when compared with TNF blockers in a large, randomized, postmarketing safety study in patients with rheumatoid arthritis aged ≥50 years with ≥1 CV factor ",
                        "CV risk",
                        "Also, higher rate of major adverse cardiovascular events (MACE), defined as cardiovascular death, myocardial infarction (MI), and stroke, observed when compared with TNF blockers ",
                        "Patients who are current or past smokers are at additional increased risk ",
                        "Discontinue in patients that have experienced MI or stroke "
                    ]
                },
                {
                    "type": "Thrombosis",
                    "description": [
                        "Also, higher rate of major adverse cardiovascular events (MACE), defined as cardiovascular death, myocardial infarction (MI), and stroke, observed when compared with TNF blockers ",
                        "Patients who are current or past smokers are at additional increased risk ",
                        "Discontinue in patients that have experienced MI or stroke "
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Hypersensitivity reactions (eg, angioedema, urticaria, rash) observed, including serious reactions; if serious hypersensitivity reaction occurs, promptly discontinue therapy while evaluating potential causes ",
                "Malignancies were observed in clinical studies; non-melanoma skin cancers reported; periodic skin examination is recommended for patients who are at increased risk for skin cancer",
                "Higher rate for all-cause mortality and for MACE (defined as CV death, myocardial infarction, and stroke) reported with another JAK inhibitor compared with TNF blockers in patients who have RA and ≥1 CV risk ",
                "Increased incidence of thrombosis, including DVT and PE, observed compared with placebo; avoid therapy in patients who may be at increased risk of thrombosis ",
                "Gastrointestinal perforation reported in clinical studies, although role of JAK inhibition in these events is unknown",
                "May increase incidence of neutropenia, lymphopenia, anemia, or elevated LFTs or lipids; monitor laboratory values at baseline and periodically during treatment",
                "Promptly investigate cause of liver enzyme elevation recommended to identify potential cases of drug-induced liver injury; interrupt therapy if increased ALT or AST observed and drug-induced liver injury is suspected, until this diagnosis is excluded "
            ],
            "specific": [
                {
                    "type": "Infection risk",
                    "description": [
                        "In patients with COVID-19, monitor for signs and symptoms of new infections during and after treatment; there is limited information regarding use in patients with COVID-19 and concomitant active serious infections; risks and benefits of treatment in COVID-19 patients with other concurrent infections should be considered",
                        "Serious and sometimes fatal infections may develop owing to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens reported; may cause reactivation of latent TB or viral infections ",
                        "Perform screening for viral hepatitis in accordance with clinical guidelines before starting therapy; unknown impact on chronic viral hepatitis reactivation ",
                        "Consider risks and benefits before initiating in patients with chronic or recurrent infection, history of serious or opportunistic infection, underlying conditions predisposing them to infection, or patients who have been exposed to tuberculosis or have resided or traveled in areas of endemic tuberculosis or mycoses ",
                        "Consider TB therapy for patients with a negative test for latent TB but who have risk factors for TB infection; consultation with a physician with expertise in TB recommended to aid in decision about whether initiating anti-TB therapy is appropriate",
                        "If a new infection develops during treatment, promptly initiate diagnostic tests appropriate for an immunocompromised patient; if necessary, initiate appropriate antimicrobial therapy and closely monitor; interrupt baricitinib therapy if patient unresponsive to treatment",
                        "If herpes zoster occurs, interrupt treatment until episode resolves"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Avoid use of live vaccines; update immunizations in agreement with current immunization guidelines before initiating",
                        "Coadministration with strong OAT3 inhibitors may increase baricitinib systemic exposure; dosage modification recommended "
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "upadacitinib",
            "description": {
                "common": "baricitinib, upadacitinib.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "abatacept",
            "description": {
                "common": "baricitinib, abatacept.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "adalimumab",
            "description": {
                "common": "baricitinib, adalimumab.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "adenovirus types 4 and 7 live, oral",
            "description": {
                "common": "baricitinib decreases effects of adenovirus types 4 and 7 live, oral by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid use of live vaccines with baricitinib. Update immunizations in agreement with current immunization guidelines before initiating baricitinib."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ado-trastuzumab emtansine",
            "description": {
                "common": "baricitinib, ado-trastuzumab emtansine.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "anakinra",
            "description": {
                "common": "baricitinib, anakinra.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "axicabtagene ciloleucel",
            "description": {
                "common": "baricitinib, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "azathioprine",
            "description": {
                "common": "baricitinib, azathioprine.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "balsalazide",
            "description": {
                "common": "balsalazide will increase the level or effect of baricitinib by  decreasing elimination. Avoid or Use Alternate Drug. Coadministration of baricitinib with strong organic anion transporter 3 (OAT3) inhibitors is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "BCG vaccine live",
            "description": {
                "common": "baricitinib decreases effects of BCG vaccine live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid use of live vaccines with baricitinib. Update immunizations in agreement with current immunization guidelines before initiating baricitinib."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "brexucabtagene autoleucel",
            "description": {
                "common": "baricitinib, brexucabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "canakinumab",
            "description": {
                "common": "baricitinib, canakinumab.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "certolizumab pegol",
            "description": {
                "common": "baricitinib, certolizumab pegol.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ciltacabtagene autoleucel",
            "description": {
                "common": "baricitinib, ciltacabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "baricitinib, cyclosporine.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "deferiprone",
            "description": {
                "common": "baricitinib, deferiprone.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "diflunisal",
            "description": {
                "common": "diflunisal will increase the level or effect of baricitinib by  decreasing elimination. Avoid or Use Alternate Drug. Coadministration of baricitinib with strong organic anion transporter 3 (OAT3) inhibitors is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "etanercept",
            "description": {
                "common": "baricitinib, etanercept.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ethacrynic acid",
            "description": {
                "common": "ethacrynic acid will increase the level or effect of baricitinib by  decreasing elimination. Avoid or Use Alternate Drug. Coadministration of baricitinib with strong organic anion transporter 3 (OAT3) inhibitors is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fingolimod",
            "description": {
                "common": "baricitinib, fingolimod.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "golimumab",
            "description": {
                "common": "baricitinib, golimumab.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idecabtagene vicleucel",
            "description": {
                "common": "baricitinib, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "infliximab",
            "description": {
                "common": "baricitinib, infliximab.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "influenza virus vaccine quadrivalent, intranasal",
            "description": {
                "common": "baricitinib decreases effects of influenza virus vaccine quadrivalent, intranasal by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid use of live vaccines with baricitinib. Update immunizations in agreement with current immunization guidelines before initiating baricitinib."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "irbesartan",
            "description": {
                "common": "irbesartan will increase the level or effect of baricitinib by  decreasing elimination. Avoid or Use Alternate Drug. Coadministration of baricitinib with strong organic anion transporter 3 (OAT3) inhibitors is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ketorolac",
            "description": {
                "common": "ketorolac will increase the level or effect of baricitinib by  decreasing elimination. Avoid or Use Alternate Drug. Coadministration of baricitinib with strong organic anion transporter 3 (OAT3) inhibitors is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lisocabtagene maraleucel",
            "description": {
                "common": "baricitinib, lisocabtagene maraleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "measles mumps and rubella vaccine, live",
            "description": {
                "common": "baricitinib decreases effects of measles mumps and rubella vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid use of live vaccines with baricitinib. Update immunizations in agreement with current immunization guidelines before initiating baricitinib."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "measles, mumps, rubella and varicella vaccine, live",
            "description": {
                "common": "baricitinib decreases effects of measles, mumps, rubella and varicella vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid use of live vaccines with baricitinib. Update immunizations in agreement with current immunization guidelines before initiating baricitinib."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "meclofenamate",
            "description": {
                "common": "meclofenamate will increase the level or effect of baricitinib by  decreasing elimination. Avoid or Use Alternate Drug. Coadministration of baricitinib with strong organic anion transporter 3 (OAT3) inhibitors is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mefenamic acid",
            "description": {
                "common": "mefenamic acid will increase the level or effect of baricitinib by  decreasing elimination. Avoid or Use Alternate Drug. Coadministration of baricitinib with strong organic anion transporter 3 (OAT3) inhibitors is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "natalizumab",
            "description": {
                "common": "baricitinib, natalizumab.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nateglinide",
            "description": {
                "common": "nateglinide will increase the level or effect of baricitinib by  decreasing elimination. Avoid or Use Alternate Drug. Coadministration of baricitinib with strong organic anion transporter 3 (OAT3) inhibitors is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nitazoxanide",
            "description": {
                "common": "nitazoxanide will increase the level or effect of baricitinib by  decreasing elimination. Avoid or Use Alternate Drug. Coadministration of baricitinib with strong organic anion transporter 3 (OAT3) inhibitors is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ocrelizumab",
            "description": {
                "common": "baricitinib and ocrelizumab both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "oxaprozin",
            "description": {
                "common": "oxaprozin will increase the level or effect of baricitinib by  decreasing elimination. Avoid or Use Alternate Drug. Coadministration of baricitinib with strong organic anion transporter 3 (OAT3) inhibitors is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "penicillin G benzathine",
            "description": {
                "common": "penicillin G benzathine will increase the level or effect of baricitinib by  decreasing elimination. Avoid or Use Alternate Drug. Coadministration of baricitinib with strong organic anion transporter 3 (OAT3) inhibitors is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pimecrolimus",
            "description": {
                "common": "baricitinib, pimecrolimus.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pioglitazone",
            "description": {
                "common": "pioglitazone will increase the level or effect of baricitinib by  decreasing elimination. Avoid or Use Alternate Drug. Coadministration of baricitinib with strong organic anion transporter 3 (OAT3) inhibitors is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pretomanid",
            "description": {
                "common": "pretomanid will increase the level or effect of baricitinib by  Other (see comment). Avoid or Use Alternate Drug. In vitro studies demonstrated that pretomanid significantly inhibits OAT3; monitor for increased adverse effects and consider dosage reduction for OAT3 substrates."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "probenecid",
            "description": {
                "common": "probenecid will increase the level or effect of baricitinib by  decreasing elimination. Avoid or Use Alternate Drug. Coadministration of baricitinib with strong organic anion transporter 3 (OAT3) inhibitors is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rilonacept",
            "description": {
                "common": "baricitinib, rilonacept.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rituximab",
            "description": {
                "common": "baricitinib, rituximab.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rituximab-hyaluronidase",
            "description": {
                "common": "baricitinib, rituximab-hyaluronidase.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rotavirus oral vaccine, live",
            "description": {
                "common": "baricitinib decreases effects of rotavirus oral vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid use of live vaccines with baricitinib. Update immunizations in agreement with current immunization guidelines before initiating baricitinib."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "siltuximab",
            "description": {
                "common": "baricitinib, siltuximab.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "smallpox (vaccinia) vaccine, live",
            "description": {
                "common": "baricitinib decreases effects of smallpox (vaccinia) vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid use of live vaccines with baricitinib. Update immunizations in agreement with current immunization guidelines before initiating baricitinib."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "baricitinib, tacrolimus.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "telmisartan",
            "description": {
                "common": "telmisartan will increase the level or effect of baricitinib by  decreasing elimination. Avoid or Use Alternate Drug. Coadministration of baricitinib with strong organic anion transporter 3 (OAT3) inhibitors is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tisagenlecleucel",
            "description": {
                "common": "baricitinib, tisagenlecleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tocilizumab",
            "description": {
                "common": "baricitinib, tocilizumab.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tofacitinib",
            "description": {
                "common": "baricitinib, tofacitinib.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "trastuzumab deruxtecan",
            "description": {
                "common": "baricitinib, trastuzumab deruxtecan.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "typhoid vaccine live",
            "description": {
                "common": "baricitinib decreases effects of typhoid vaccine live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid use of live vaccines with baricitinib. Update immunizations in agreement with current immunization guidelines before initiating baricitinib."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "valsartan",
            "description": {
                "common": "valsartan will increase the level or effect of baricitinib by  decreasing elimination. Avoid or Use Alternate Drug. Coadministration of baricitinib with strong organic anion transporter 3 (OAT3) inhibitors is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "varicella virus vaccine live",
            "description": {
                "common": "baricitinib decreases effects of varicella virus vaccine live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid use of live vaccines with baricitinib. Update immunizations in agreement with current immunization guidelines before initiating baricitinib."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vedolizumab",
            "description": {
                "common": "baricitinib, vedolizumab.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "yellow fever vaccine",
            "description": {
                "common": "baricitinib decreases effects of yellow fever vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid use of live vaccines with baricitinib. Update immunizations in agreement with current immunization guidelines before initiating baricitinib."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "zoster vaccine live",
            "description": {
                "common": "baricitinib increases effects of zoster vaccine live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid use of live vaccines with baricitinib. Update immunizations in agreement with current immunization guidelines before initiating baricitinib."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ifosfamide",
            "description": {
                "common": "ifosfamide, baricitinib.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mechlorethamine",
            "description": {
                "common": "mechlorethamine, baricitinib. immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution should be taken in patients on concomitant immunosuppressants or with impaired immune systems because of increased risk for serious infections. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trastuzumab",
            "description": {
                "common": "trastuzumab, baricitinib.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trastuzumab deruxtecan",
            "description": {
                "common": "trastuzumab deruxtecan, baricitinib.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ublituximab",
            "description": {
                "common": "ublituximab and baricitinib both increase  immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Owing to potential additive immunosuppressive effects, consider duration of effect and mechanism of action of these therapies if coadministered"
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Upper respiratory tract infections",
            "percent": "16.3"
        },
        {
            "name": "ALT",
            "percent": "3"
        },
        {
            "name": "x ULN",
            "percent": "18.1"
        },
        {
            "name": "AST",
            "percent": "3"
        },
        {
            "name": "x ULN",
            "percent": "11.8"
        },
        {
            "name": "Increased ALT",
            "percent": "1.3-4.7"
        },
        {
            "name": "AST",
            "percent": "2.7-2.8"
        },
        {
            "name": "Nausea",
            "percent": "1-2"
        },
        {
            "name": "Platelet elevations",
            "percent": "1-1.4"
        },
        {
            "name": "Herpes zoster infection",
            "percent": "0.8-1.4"
        },
        {
            "name": "Herpes simplex infection",
            "percent": "600,000"
        },
        {
            "name": "Reported incidence less than placebo",
            "percent": "3"
        },
        {
            "name": "Thrombocytosis",
            "percent": "7.9"
        },
        {
            "name": "cells",
            "percent": "5"
        },
        {
            "name": "mm",
            "percent": "4.5"
        },
        {
            "name": "CPK",
            "percent": "1000"
        },
        {
            "name": "x ULN",
            "percent": "3"
        },
        {
            "name": "Neutropenia",
            "percent": "2.2"
        },
        {
            "name": "cells",
            "percent": "1.5"
        },
        {
            "name": "mm",
            "percent": "1.5"
        },
        {
            "name": "Deep vein thrombosis",
            "percent": "1.5"
        },
        {
            "name": "Pulmonary embolism",
            "percent": "1"
        },
        {
            "name": "Urinary tract infection",
            "percent": "0.3"
        },
        {
            "name": "Acne",
            "percent": null
        },
        {
            "name": "Neutropenia",
            "percent": null
        }
    ]
}